Cytokinetics EVP Sells Over $100K in Stock

Insider sale represents a 3.57% decrease in executive's ownership stake

Mar. 16, 2026 at 10:12pm

Got story updates? Submit your updates here. ›

Cytokinetics, Incorporated (NASDAQ:CYTK) Executive Vice President Andrew Callos sold 1,709 shares of the company's stock on Monday, March 16th, for a total transaction value of $104,300.27. Following the sale, Callos now owns 46,149 shares in the biopharmaceutical company, valued at approximately $2.8 million.

Why it matters

Insider transactions, such as stock sales by company executives, can provide insights into management's views on a company's prospects. While a single transaction does not necessarily indicate a broader trend, ongoing insider selling activity may signal potential concerns or a lack of confidence in the company's future performance.

The details

Callos' stock sale represents a 3.57% decrease in his ownership stake in Cytokinetics. The shares were sold at an average price of $61.03. Callos has made several other stock sales in recent months, including transactions in March, February, and January.

  • The stock sale occurred on Monday, March 16, 2026.
  • Callos has made other stock sales in March, February, and January of 2026.

The players

Andrew Callos

Executive Vice President of Cytokinetics, Incorporated.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

What they’re saying

“This trade represents a 3.57% decrease in their ownership of the stock.”

— Andrew Callos, Executive Vice President (marketbeat.com)

The takeaway

While a single insider sale does not necessarily indicate broader concerns, ongoing insider selling activity can be a signal for investors to monitor a company's performance and management's confidence in its future prospects.